REFERENCES
- Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1,2009; 1–161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentGL.pdf. Accessed February 15,2010.
- Smith C and D:A:D Study Group. Association between modifiable and non-modifiable risk factors and specific causes of death in the HAART era: the data collection on adverse events of anti-HIV drug study. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infec-tions; February 2009; Montreal, Canada. Abstract 145.
- Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibi-tor raltegravir as part of combination therapy in treat-ment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125–133.
- Lennox JL, DeJesus E, Lazzarin A, et al. Safety and effi-cacy of raltegravir-based versus efavirenz-based com-bination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised con-trolled trial. Lancet. 2009;374:796–806.
- Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.
- Elion R, de Jesus E, Sension M, et al. Once-daily abacavir/ lamivudine and ritonavir-boosted atazanavir for the treat-ment of HIV-1 infection in antiretroviral-naIve patients: a 48-week pilot study. HIV Clin Trials. 2008;9:152–163.
- Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J CardioL 2002;90:22i–29i.
- Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Athero-scler Rep. 2004;6:381–387.
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Associa-tion. Circulation. 2003;107;499–511.
- Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflam-mation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;15:1788–1795.
- Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med. 2008;16:62–68.
- Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184IN mutations in combina-tion with single thymidine analog mutations on nucleo-side reverse transcriptase inhibitor resistance. AIDS. 2004;18:1691–1696.
- Quan Y, Brenner BG, Oliveira M, et al. Lamivudine can exert a modest antiviral effect against human immuno-deficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother 2003;47:747–754.
- Katlama C, Clotet B, Plettenberg A, et al. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a ran-domized, double-blind trial. HIV Med. 2001;2:27–34.
- Miller V, StOrmer M, Staszewski S, et al. The M184V muta-tion in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS. 1998;12:705–712.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143–3421.
- Harris M, Larsen G, Montaner JS. Exacerbation of depres-sion associated with starting raltegravir: a report of four cases. AIDS. 2008;22:1890–1892.
- Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and litera-ture review. AIDS Patient Care STDS. 2009;23:689–690.
- Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22:1382–1384.
- Masia M, Enriquez R, Sirvent A, et al. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect. 2010;61:189— 190.
- Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Ath-erosclerosis. 2009;207:524–529.